PARIS & NOTTINGHAM, England–(BUSINESS WIRE)–May 10, 2022–
Iktos, a company specializing in artificial intelligence (AI) for the design of new medicines, and Sygnature Discovery, a leading integrated CRO in the field of drug discovery, headquartered in Nottingham, UK , which has expertise in a range of therapeutic and biological target classes, today announced an agreement to collaborate in the field of AI for new drug design.
As part of the 3-year agreement, Sygature will deploy Iktos de novo Makya™ generative design software, which will be used by Sygnature scientists to facilitate the rapid and efficient design of new compounds and accelerate track access/runway optimization, further enhancing Sygnature’s expertise Discovery in drug design by providing its integrated drug discovery solutions to its global customer network.
Over the past few years, Iktos has become one of the world leaders in AI for drug design, establishing multiple collaborations with renowned pharmaceutical companies and successfully developing Makya™ AI software platforms for drug design. new drugs and Spaya™ for synthesis planning.
Makya™, a generative solution driven by AI de novo design software for multi-parameter optimization (MPO), is available either as a SaaS platform or for implementation at the customer’s premises or in the customer’s Virtual Private Cloud (VPC). Makya’s user-friendly interface allows it to be used by medicinal or computer chemists, and Makya can also be used as a Python package through a Jupyter notebook interface. Makya is based on Iktos’ generative AI technology, which speeds up and improves the drug discovery process by automatically designing new virtual molecules that have desired activities to treat a given disease. It is a new solution, validated by numerous collaborations, to one of the main challenges in drug design: the rapid identification of molecules that simultaneously satisfy several parameters, such as potency, selectivity, security and project-specific properties.
Sygature Discovery serves its growing customer base with fully integrated drug discovery services, from target validation to preclinical candidate screening. The company has a relentless focus on quality and continually seeks to improve its ability to deliver new therapies to the clinic.
Colin Sambrook-Smith, Director of Computer Science at Sygnature Discovery commented:
“Later-stage lead optimization projects routinely generate substantial datasets that are ideally placed to be mined by AI and machine learning technologies. Our experience with Iktos Makya AI/ML technology demonstrates that it generates high quality compound ideas, QSAR models can be quickly updated, and the interface allows us to distribute the software widely and quickly. We believe Makya will allow us to combine our proven expertise in medicinal and computational chemistry with the advantages of AI/ML technologies to impact compound design. That’s why we chose Makya to improve the way we help our clients with their lead optimization projects, with a view to reducing the number of compounds needed to identify preclinical candidates and thereby reducing overall costs and lead times.
“We are very pleased to collaborate with Sygnature Discovery, they are truly a leading integrated CRO in drug discovery and with an excellent track record. We are delighted and proud to announce our first multi-year collaboration agreement in the dynamic drug discovery industry. CRO and to have the scientists use our software to accelerate their customers’ discovery programs,” said Yann Gaston-Mathé, co-founder and CEO of Iktos. “We are more committed than ever to bringing our technology to available to biopharmaceutical companies worldwide and to maximize the impact of AI on drug discovery productivity.”
Incorporated in October 2016, Iktos is a start-up specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and the design of new drugs. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which allows, from existing data, to design molecules optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology allows significant productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both in the form of professional services and in the form of a SaaS software platform, Makya™. Iktos also develops Spaya™, a synthesis planning software based on Iktos proprietary artificial intelligence technology for retrosynthesis.
More information on: http://www.iktos.ai/
Sygature Discovery is a leading independent integrated drug discovery and non-clinical services company. Backed by private equity since 2017, the company operates fully equipped research facilities in Nottingham and Alderley Park, UK, housing over 500 staff (over 80% of scientists hold PhDs), and has an office in Cambridge, MA, and South San Francisco, CA, in the United States.
Their experienced drug hunters have all the professional skills and know-how needed to undertake the most demanding research programs and lead them from target validation, outcome identification, outcome optimization and leads to the candidate for preclinical development. Sygnature’s in vivo pharmacology arm was created through the incorporation of RenaSci, acquired in 2018, into Sygnature’s fully integrated drug discovery platform. In 2020, Sygnature added to this the acquisitions of in vivo oncology company Alderley Oncology and DMPK supplier XenoGesis.
Since 2011, 37 compounds discovered by Sygnature for customers have entered formal regulatory development and, to date, 20 of them have progressed to clinical trials (Phases I, II and III). In 2017, Sygature Discovery received the prestigious Queen’s Award for Enterprise for International Trade and last year won both the Medilink Outstanding Achievement Award and the Bionow Company of the Year Award.
More information on: https://www.sygaturediscovery.com/
Show source version on businesswire.com:https://www.businesswire.com/news/home/20220510005247/en/
Yann Gaston-Mathé (CEO)
+33 6 30 07 99 26 Signature:
Discovery of the signature
Telephone: +44 (0)115 941 5401
Email: [email protected]
KEYWORD: EUROPE UNITED KINGDOM FRANCE
KEYWORD INDUSTRY: RESEARCH TECHNOLOGY OTHER TECHNOLOGIES OTHER HEALTH BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH SCIENCE OTHER SCIENCES
Copyright BusinessWire 2022.
PUBLISHED: 05/10/2022 03:00 AM/DISC: 05/10/2022 03:02 AM